• About us
• Contact

Advertisement

Organisation › Details

Merck KGaA

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene- editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of €15.3 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. *

 

	Start	1668-01-01 established_pre
	Group	Merck (DE) (Group)
	Industry	pharmaceutical
	Industry 2	reagents (bio/biochemical)
	Person	Garijo, Belén (Merck (DE) 202007– promoted Deputy CEO before CEO of Merck Serono before COO before Sanofi)
	Street	250 Frankfurter Str.
	City	64293 Darmstadt
	Tel	+49-6151-72-0
		Address record changed: 2024-01-05
Basic data	Employees	I: 50,001 to 100,0 (2023-12-31)
	Currency	EUR
	Annual sales	20,993,000,000 (sales, net, consolidated (2023) 2023-12-31)
	Profit	2,834,000,000 (2023-12-31)
	Cash	1,982,000,000 (2023-12-31)
		* Document for »About Section«: Merck KGaA. (3/4/19). "Press Release: Merck Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology". Darmstadt.
		Record changed: 2024-08-17

Advertisement

More documents for Merck (DE) (Group)

• [1] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
• [2] Iktos SAS. (3/9/23). "Press Release: Iktos Raises € 15.5m Series A Round to Expand Its Artificial Intelligence-based Drug Discovery Technologies and Solutions". Paris & Lausanne....
• [3] BioGeneration Ventures B.V.. (11/8/22). "Press Release: BGV Appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor". Amsterdam....
• [4] genOway S.A.. (9/8/22). "Press Release: Sigma-Aldrich and genOway Expand Their CRISPR/Cas9 Strategic Alliance". St. Louis, MO & Lyon....
• [5] iOmx Therapeutics AG. (10/5/21). "Press Release: iOmx Therapeutics Raises EUR 65 Million in Series B Round". Martinsried....
• [6] MoonLake Immunotherapeutics AG. (7/1/21). "Press Release: MoonLake Immunotherapeutics Appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO". Zug....
• [7] MoonLake Immunotherapeutics AG. (5/3/21). "Press Release: MoonLake In-licensing and Launch". Zug....
• [8] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
• [9] Merck KGaA. (7/1/20). "Press Release: Merck Advances Bioprocessing Capabilities with Raman Technology Sensor Acquisition". Darmstadt....
• [10] Scipio Bioscience SAS. (2/25/20). "Press Release: Scipio Bioscience Raises €6.0 M Series A Financing". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.